Methotrexate for the treatment of osteoarthritis: a systematic review and meta-analysis of randomized controlled trials

Метотрексат для лечения остеоартрита: систематический обзор и метаанализ рандомизированных контролируемых исследований
Huzaifa Ahmad Cheema, Farah Salahuddin, Tanmayee Mareedu, Hafseena Noorayingarath, Sumayya Umar, Ashesh Das, Lavinia Bucataru, Charan Madhav Reddy Seelam, Nadia Ahmed, Karuna Sree Podila, Aneez Muhammed, Avni Bhatia, Hareem Farooq
2025-11-04

methotrexateosteoarthritisrandomized controlled trialsstiffnesssystematic review and meta-analysis
Abstract Methotrexate (MTX) has been proposed to treat osteoarthritis (OA) because of its anti-inflammatory effects, but randomized trial results are inconsistent. We performed a systematic review and meta-analysis of randomized trials to clarify MTX’s efficacy and safety in adults with knee or hand OA. We searched MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov from inception through July 2025. Randomized controlled trials (RCTs) comparing MTX (any dose) with placebo were eligible. We pooled continuous outcomes as mean differences (MDs) and standardized mean differences (SMDs) and dichotomous outcomes as risk ratios (RRs) using random-effects models. Seven RCTs with follow-up ranging between 3 and 12 months were included. MTX did not significantly reduce overall pain compared to placebo (SMD −0.22; 95% CI, −0.48 to 0.04; I² = 62%). MTX reduced stiffness (SMD −0.29; 95% CI, −0.51 to −0.08; I² = 36%), a finding that was consistent in subgroup analyses by joint site (knee and hand). No significant benefits were observed for physical function (SMD −0.50; 95% CI, −1.14 to 0.14; I² = 93%), WOMAC total score (SMD −0.08; 95% CI, −0.33 to 0.17; I² = 93%), or quality-of-life measures (SMD −0.43; 95% CI, −1.08 to 0.22; I² = 90%). Rates of adverse events and serious adverse events were similar between groups. MTX provides a consistent reduction in stiffness but does not significantly reduce pain, improve function, or enhance quality of life. Phenotype-driven, dose-optimized, and longer-term trials that incorporate imaging or synovial biomarkers are needed to define who may benefit the most.
1
A systematic review and meta-analysis included seven randomized controlled trials evaluating methotrexate versus placebo in adults with knee or hand osteoarthritis.
2
Adverse-event and serious-adverse-event rates were similar between methotrexate and placebo groups; longer-term, phenotype-driven, dose-optimized trials are needed.
3
Methotrexate did not significantly reduce overall pain compared with placebo (SMD −0.22; 95% CI, −0.48 to 0.04).
4
Methotrexate showed no significant benefits for physical function, WOMAC total scores, or quality-of-life measures, with substantial heterogeneity for several outcomes.
5
Methotrexate significantly reduced stiffness (SMD −0.29; 95% CI, −0.51 to −0.08), consistently across knee and hand osteoarthritis subgroups.

Adults with knee or hand osteoarthritis treated with methotrexate versus placebo

Methotrexate efficacy and safety, particularly its effects on stiffness, pain, physical function, quality of life, and adverse events

Publication Details
Publication Date
2025-11-04
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
Huzaifa Ahmad Cheema
Farah Salahuddin
Tanmayee Mareedu
Hafseena Noorayingarath
Sumayya Umar
Ashesh Das
Lavinia Bucataru
Charan Madhav Reddy Seelam
Nadia Ahmed
Karuna Sree Podila
Aneez Muhammed
Avni Bhatia
Hareem Farooq
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%